Xeris Biopharma Holdings, Inc.
XERS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $203,070 | $163,914 | $110,248 | $49,590 |
| % Growth | 23.9% | 48.7% | 122.3% | – |
| Cost of Goods Sold | $36,832 | $28,645 | $22,634 | $13,318 |
| Gross Profit | $166,238 | $135,269 | $87,614 | $36,272 |
| % Margin | 81.9% | 82.5% | 79.5% | 73.1% |
| R&D Expenses | $25,560 | $22,341 | $20,966 | $25,160 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $163,481 | $146,095 | $137,745 | $125,718 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $10,843 | $10,843 | $10,843 | $550 |
| Operating Expenses | $199,884 | $179,279 | $169,554 | $151,428 |
| Operating Income | -$33,646 | -$44,010 | -$81,940 | -$115,156 |
| % Margin | -16.6% | -26.8% | -74.3% | -232.2% |
| Other Income/Exp. Net | -$23,458 | -$19,494 | -$14,144 | -$7,569 |
| Pre-Tax Income | -$57,104 | -$63,504 | -$96,084 | -$122,725 |
| Tax Expense | -$2,268 | -$1,249 | -$1,424 | $0 |
| Net Income | -$54,836 | -$62,255 | -$94,660 | -$122,725 |
| % Margin | -27% | -38% | -85.9% | -247.5% |
| EPS | -0.37 | -0.45 | -0.7 | -1.55 |
| % Growth | 17.8% | 35.7% | 54.8% | – |
| EPS Diluted | -0.37 | -0.45 | -0.7 | -1.55 |
| Weighted Avg Shares Out | 146,773 | 137,675 | 135,629 | 79,027 |
| Weighted Avg Shares Out Dil | 146,773 | 137,675 | 135,629 | 79,027 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5,321 | $4,751 | $2,578 | $313 |
| Interest Expense | $33,175 | $26,609 | $14,102 | $7,180 |
| Depreciation & Amortization | $12,625 | $13,160 | $12,668 | $1,879 |
| EBITDA | -$13,994 | -$23,735 | -$69,314 | -$113,666 |
| % Margin | -6.9% | -14.5% | -62.9% | -229.2% |